GB9924057D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB9924057D0
GB9924057D0 GBGB9924057.4A GB9924057A GB9924057D0 GB 9924057 D0 GB9924057 D0 GB 9924057D0 GB 9924057 A GB9924057 A GB 9924057A GB 9924057 D0 GB9924057 D0 GB 9924057D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9924057.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB9924057.4A priority Critical patent/GB9924057D0/en
Publication of GB9924057D0 publication Critical patent/GB9924057D0/en
Priority to JP2001529798A priority patent/JP2003511426A/en
Priority to EP00972703A priority patent/EP1239922A2/en
Priority to AU11346/01A priority patent/AU1134601A/en
Priority to PCT/EP2000/009883 priority patent/WO2001026737A2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB9924057.4A 1999-10-11 1999-10-11 Organic compounds Ceased GB9924057D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9924057.4A GB9924057D0 (en) 1999-10-11 1999-10-11 Organic compounds
JP2001529798A JP2003511426A (en) 1999-10-11 2000-10-09 Assay method
EP00972703A EP1239922A2 (en) 1999-10-11 2000-10-09 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator
AU11346/01A AU1134601A (en) 1999-10-11 2000-10-09 Assay method
PCT/EP2000/009883 WO2001026737A2 (en) 1999-10-11 2000-10-09 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924057.4A GB9924057D0 (en) 1999-10-11 1999-10-11 Organic compounds

Publications (1)

Publication Number Publication Date
GB9924057D0 true GB9924057D0 (en) 1999-12-15

Family

ID=10862542

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9924057.4A Ceased GB9924057D0 (en) 1999-10-11 1999-10-11 Organic compounds

Country Status (5)

Country Link
EP (1) EP1239922A2 (en)
JP (1) JP2003511426A (en)
AU (1) AU1134601A (en)
GB (1) GB9924057D0 (en)
WO (1) WO2001026737A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2305273T3 (en) * 2001-05-07 2008-11-01 Centre National De La Recherche Scientifique (Cnrs) FRAGMENTS OF THE ORPHAN RECEIVER RELATED TO THE RETINOIC ACID (ROR) UNDERSTANDING THE DOMAIN OF UNION TO THE BINDING (LBD), THE CRYSTALLINE STRUCTURE OF THE ROR-BETA LBD AND ITS APPLICATIONS.
EP1501867A1 (en) * 2002-04-29 2005-02-02 Novartis AG Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
AU2003292144A1 (en) * 2002-11-27 2004-06-18 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0552612A3 (en) * 1992-01-22 1993-10-20 Hoffmann La Roche Methods for determining and isolating compounds which bind directly to nucleosolic proteins
HUT75128A (en) * 1994-03-30 1997-04-28 Ciba Geigy Ag Screening method using the rzr receptor family
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
FR2776388B1 (en) * 1998-03-20 2006-04-28 Lipha USE OF ROR FAMILY RECEPTORS FOR SCREENING OF SUBSTANCES USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS

Also Published As

Publication number Publication date
AU1134601A (en) 2001-04-23
EP1239922A2 (en) 2002-09-18
JP2003511426A (en) 2003-03-25
WO2001026737A3 (en) 2001-10-18
WO2001026737A2 (en) 2001-04-19

Similar Documents

Publication Publication Date Title
GB9903759D0 (en) Organic compounds
GB9903547D0 (en) Organic compounds
GB9907097D0 (en) Organic compounds
GB9908533D0 (en) Organic compounds
GB9903548D0 (en) Organic compounds
GB9902938D0 (en) Organic compounds
GB9907908D0 (en) Organic compounds
GB9910119D0 (en) Organic compounds
GB9924057D0 (en) Organic compounds
GB9910965D0 (en) Organic compounds
GB9907094D0 (en) Organic compounds
GB9904423D0 (en) Organic compounds
GB9903545D0 (en) Organic compounds
GB9903544D0 (en) Organic compounds
GB9903440D0 (en) Organic compounds
GB9902940D0 (en) Organic compounds
GB9902939D0 (en) Organic compounds
GB9903667D0 (en) Organic compounds
GB9901939D0 (en) Organic compounds
GB9900293D0 (en) Organic compounds
GB9900230D0 (en) Organic compounds
GB9903876D0 (en) Organic compounds
GB9903878D0 (en) Organic compounds
GB9913817D0 (en) Organic compounds
GB9911926D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)